comparemela.com
  1. Home
  2. Live Updates
  3. Prelude Corporation Preludedx - Breaking News

Latest Breaking News On - Prelude corporation preludedx - Page 3 : comparemela.com

PreludeDx™ Announces New Contract with MediNcrease Health Plans for its Novel DCIS Test, DCISionRT®

/PRNewswire/ Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it.

United statesDan forchePreludedx dcisionAndrew wadeCory dunnNational cancer institutePrelude corporation preludedxPrelude corporationMedincrease healthMedincrease provider networkUniversity of california san franciscoMedincrease enables availabilityMedincrease health plansLinda plasterChief executive officerCalifornia san francisco

GenesisCare and PreludeDx(TM) present compelling Australian-first DCISionRT Study Interim Analysis during Breast Cancer Awareness Month 45% change in treatment recommendations when using DCISionRT

/PRNewswire/ GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation (PreludeDx(TM)), a leader in molecular diagnostics.

United statesNew south walesUnited kingdomUniversity of california san franciscoDan forcheBruce mannPrnewswire genesiscareYvonne zissiadisTroy bremerTherapeutic goods associationNational cancer institutePrelude corporation preludedxPrelude corporationAustralasian international breast congressBreast cancer network australiaBreast cancer services for royal melbourne

GenesisCare and PreludeDx(TM) present compelling Australian-first DCISionRT Study Interim Analysis during Breast Cancer Awareness Month 45% change in treatment recommendations when using DCISionRT

/PRNewswire/ GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation (PreludeDx(TM)), a leader in molecular diagnostics.

United statesNew south walesUnited kingdomUniversity of california san franciscoDan forcheBruce mannPrnewswire genesiscareYvonne zissiadisTroy bremerTherapeutic goods associationNational cancer institutePrelude corporation preludedxPrelude corporationAustralasian international breast congressBreast cancer network australiaBreast cancer services for royal melbourne

PreludeDx Presents New Data at AACR Confirming No Significant Radiation Benefit in DCISionRT Low-risk Patients

/PRNewswire/ Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced compelling.

United statesDan forcheAndrew wadeRachel rabinovitchCory dunnNational cancer institutePrelude corporation preludedxPrelude corporationAmerican association for cancer researchUniversity of coloradoUniversity of california san franciscoRisk recurrenceAmerican associationCancer researchSpecial conferenceRadiation oncology

PreludeDx™ Closes $20 Million in Funding to Advance Growth Initiatives and Development of Its Precision Medicine Portfolio

/PRNewswire/ Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that.

United statesDan forcheAndrew wadeAlejandro sanchezCory dunnEvidity health capitalNational cancer institutePrelude corporation preludedxPrelude corporationUniversity of california san franciscoJoin boardManaging directorCalifornia san franciscoKnow yourFjord venturesDecision score

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.